# Retractable Technologies, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Retractable Technologies, Inc).

## Overview

Retractable Technologies Inc. designs and manufactures safety-engineered injection devices, including syringes and needles, for healthcare use. The company serves domestic and international customers from the United States and also sources some finished goods through manufacturing arrangements in China.

## Products & services

• Safety syringes and injection devices
• Needles and related sharps products
• EasyPoint® safety needle products
• Vaccination and flu-season syringe products
• Domestic manufacturing of selected product lines

- **Safety syringes** (55%) — Injection syringes used for vaccination and general medical administration, including domestic production.
- **Needles and sharps products** (20%) — Needles and related safety-engineered sharps products sold to healthcare customers.
- **EasyPoint® products** (15%) — EasyPoint® safety needle products used in healthcare settings and retail pharmacy channels.
- **International sales** (10%) — Products sold to overseas customers, including some shipments sourced from China.

- Safety syringes and injection devices
- Needles and related sharps products
- EasyPoint® safety needle products
- Vaccination and flu-season syringe products
- Domestic manufacturing of selected product lines

## Customers

The company sells primarily into healthcare distribution channels, including general line distributors and retail pharmacy customers. It also serves domestic customers tied to vaccination programs and international buyers that purchase selected syringe and needle products. Demand can vary by flu season, vaccination activity, and distributor inventory levels.

- **General line distributors** (primary) — Buy syringes and needles for resale into healthcare supply chains and manage inventory based on demand.
- **Retail pharmacy customers** (secondary) — Buy EasyPoint® products for vaccination and flu-season use, where seasonal demand can be important.
- **Vaccination program customers** (primary) — Purchase syringes and related products for immunization campaigns and public health use.
- **International healthcare customers** (secondary) — Buy selected syringe and needle products, including discounted EasyPoint® sales in some markets.

- General line distributors buying syringes for broad healthcare supply
- Retail pharmacy customers purchasing EasyPoint® products for flu season
- Vaccination-related buyers stocking syringes and needles
- International customers sourcing selected products and product mixes
- Customers sensitive to inventory levels and seasonal demand patterns

## Geography

Retractable Technologies is based in the United States, where it also manufactures a meaningful portion of its products. The company sells internationally as well, and some products are sourced from China or shipped directly from China to customers, creating exposure to trade policy and cross-border supply chains.

- United States is the core manufacturing and domestic sales base
- International sales contribute to revenue and product mix
- Some finished goods are sourced from China under supply arrangements
- Direct shipments from China to customers affect inventory and logistics
- Tariffs materially affect both domestic manufacturing economics and imports

## Strategy

The company’s strategic focus is to expand domestic manufacturing capacity and reduce reliance on imported finished goods. It also seeks to manage product mix, seasonal demand, and distributor relationships while preserving liquidity through operations, investments, and other available sources of cash.

- **Increase domestic manufacturing** (short-term) — Reduces dependence on imported supply and supports tariff-sensitive products.
- **Optimize product mix** (medium-term) — Syringes and EasyPoint® products can support better pricing and demand patterns.
- **Preserve liquidity** (short-term) — Operations, tariffs, and capital spending require flexible funding sources.

- Expand U.S. manufacturing for products previously sourced abroad
- Invest in molds and equipment to support domestic production
- Manage product mix toward higher-value syringe and EasyPoint® products
- Use investments and cash reserves to support operating needs
- Maintain distributor relationships and seasonal selling opportunities

## Risks

The business is exposed to tariff policy, supply-chain disruption, and the cost of shifting more production into the United States. It also faces demand volatility from vaccination trends, distributor inventory swings, and seasonal flu patterns, while accounting estimates for rebates and inventory write-offs can affect reported results.

- **Tariffs on China-imported products** [high] — Imported syringes, needles, and other products are exposed to high tariff rates.
- **Distributor inventory overhang** [high] — Customers may hold excess vaccination inventory, reducing reorder demand.
- **Seasonal and vaccination demand swings** [medium] — Flu season and public acceptance of vaccinations drive volume variability.
- **Manufacturing transition risk** [high] — Moving production domestically requires equipment, molds, and workforce ramp-up.
- **Rebate and inventory reserve estimation** [medium] — Distributor rebates and inventory-related write-offs depend on judgment and assumptions.

- Tariffs on China-sourced products can materially raise costs
- Domestic manufacturing expansion requires capital and labor spending
- Distributor inventory overhang can suppress near-term demand
- Vaccination sentiment can affect syringe and needle volumes
- Product mix and inventory write-offs can pressure margins

## Accounting

Key accounting judgments include customer rebate reserves, inventory valuation, and unrealized gains or losses on debt and equity securities. Seasonality and distributor inventory levels can affect revenue timing, while tariff-related costs, product expiration write-offs, and securities fair value changes can materially move reported earnings and cash flow.

- **Customer rebate reserves** — Can materially affect accounts payable and net income
- **Inventory valuation and write-offs** — Affects cost of manufactured product and gross margin
- **Fair value of debt and equity securities** — Affects net income and operating cash flow reconciliation
- **Tariff-related cost capitalization/expense** — Raises cost of sales and reduces reported margins

- Customer rebate reserves depend on distributor claims and inventory assumptions
- Inventory write-offs can rise when products near expiration
- Fair value changes in securities affect earnings and cash flow
- Tariff costs are embedded in cost of manufactured product
- Seasonal demand affects quarterly comparability for syringe sales

---

*Last updated: 2026-04-29T04:51:59.156533+00:00*